bit.bio Announced As Inaugural Partner Of Ginkgo Bioworks' New Technology Network; bit.bio's ioCells Portfolio Of Human Cells For Research And Drug Discovery Can Be Integrated Into Ginkgo's Platform Ecosystem
Portfolio Pulse from Benzinga Newsdesk
bit.bio has been announced as the inaugural partner of Ginkgo Bioworks' new technology network. This partnership will allow bit.bio's ioCells portfolio of human cells, designed for research and drug discovery, to be integrated into Ginkgo's platform ecosystem.
February 28, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ginkgo Bioworks, trading under the symbol DNA, partners with bit.bio to enhance its platform ecosystem with bit.bio's ioCells for research and drug discovery.
The partnership with bit.bio is likely to enhance Ginkgo Bioworks' offerings in the biotech space, particularly in research and drug discovery, potentially leading to increased interest and investment in DNA's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90